What is Countable Labs?
Countable Labs is a biotechnology firm dedicated to enhancing precision genomics through pioneering DNA quantification technologies. Their innovative molecular measurement solutions are engineered to elevate the accuracy, sensitivity, and accessibility of genomic analysis. These tools empower researchers and healthcare professionals to derive more precise biological insights. By refining existing PCR-based technologies, Countable Labs aims to streamline complex laboratory workflows and support a broad spectrum of applications, including diagnostics, biomarker discovery, gene therapy development, and other critical areas within the life sciences. The company's objective is to facilitate the generation of more dependable and actionable genomic data.
How much funding has Countable Labs raised?
Countable Labs has raised a total of $26M across 1 funding round:
Unspecified
$26M
Unspecified (2026): $26M with participation from Primer Ventures, ARCH Venture Partners, and F-Prime Capital Partners
Key Investors in Countable Labs
Primer Ventures
Primer Ventures is an investment firm dedicated to partnering with visionary entrepreneurs to transform healthcare through innovation. They focus on early-stage investments in life science tools and therapeutics, emphasizing breakthrough innovations in genomics, synthetic biology, and molecular diagnostics.
ARCH Venture Partners
ARCH Venture Partners is a leading earlystage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
F-Prime Capital Partners
Founded in 2002, F-Prime Capital provides a team of investors, engineers, doctors, and scientists dedicated to investing in health care and technology for other companies. F-Prime Capital is located in Massachusetts.
What's next for Countable Labs?
The substantial enterprise-level capital infusion positions Countable Labs for accelerated growth and market expansion. This strategic backing is likely to be directed towards scaling operations, enhancing research and development capabilities, and potentially broadening the commercialization of their advanced DNA quantification technologies. The company's focus on improving genomic analysis accuracy and accessibility suggests a trajectory aimed at becoming a key player in the precision medicine and diagnostics markets. Future developments may include strategic partnerships and the integration of their technologies into clinical settings, further solidifying their impact on life sciences.
See full Countable Labs company page
